10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# CLEC7A Antibody (N-term) Blocking peptide
**Synthetic peptide**
**Catalog # BP13369a**

## Specification

### CLEC7A Antibody (N-term) Blocking peptide - Product Information

Primary Accession Q9BXN2

### CLEC7A Antibody (N-term) Blocking peptide - Additional Information

**Gene ID** 64581

**Other Names**
C-type lectin domain family 7 member A, Beta-glucan receptor, C-type lectin superfamily member 12, Dendritic cell-associated C-type lectin 1, DC-associated C-type lectin 1, Dectin-1, CLEC7A, BGR, CLECSF12, DECTIN1

**Target/Specificity**
The synthetic peptide sequence used to generate the antibody AP13369a was selected from the N-term region of CLEC7A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### CLEC7A Antibody (N-term) Blocking peptide - Protein Information

**Name** CLEC7A (HGNC:14558)

**Function**
Lectin that functions as a pattern recognizing receptor (PRR) specific for beta-1,3-linked and beta-1,6-linked glucans, which constitute cell wall constituents from pathogenic bacteria and fungi (PubMed:<a href="http://www.uniprot.org/citations/11567029" target="_blank">11567029</a>, PubMed:<a href="http://www.uniprot.org/citations/12423684" target="_blank">12423684</a>). Necessary for the TLR2-mediated inflammatory response and activation of NF-kappa-B: upon beta-glucan binding, recruits SYK via its ITAM motif and promotes a signaling cascade that activates some CARD domain-BCL10-MALT1 (CBM) signalosomes, leading to the activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (By similarity). Enhances cytokine production in macrophages and dendritic cells (By similarity). Mediates production of reactive oxygen species in the cell (By similarity). Mediates phagocytosis of

C.albicans conidia (PubMed:<a href="http://www.uniprot.org/citations/17230442" target="_blank">17230442</a>). Binds T-cells in a way that does not involve their surface glycans and plays a role in T-cell activation. Stimulates T-cell proliferation. Induces phosphorylation of SCIMP after binding beta-glucans (By similarity).

**Cellular Location**
Cell membrane; Single-pass type II membrane protein [Isoform 6]: Cytoplasm.

**Tissue Location**
Highly expressed in peripheral blood leukocytes and dendritic cells. Detected in spleen, bone marrow, lung, muscle, stomach and placenta.

## CLEC7A Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

## CLEC7A Antibody (N-term) Blocking peptide - Images

## CLEC7A Antibody (N-term) Blocking peptide - Background

This gene encodes a member of the C-type lectin/C-typelectin-like domain (CTL/CTLD) superfamily. The encoded glycoproteinis a small type II membrane receptor with an extracellular C-typelectin-like domain fold and a cytoplasmic domain with animmunoreceptor tyrosine-based activation motif. It functions as apattern-recognition receptor that recognizes a variety ofbeta-1,3-linked and beta-1,6-linked glucans from fungi and plants,and in this way plays a role in innate immune response. Alternatetranscriptional splice variants, encoding different isoforms, havebeen characterized. This gene is closely linked to other CTL/CTLDsuperfamily members on chromosome 12p13 in the natural killer genecomplex region.

## CLEC7A Antibody (N-term) Blocking peptide - References

de Koning, H.D., et al. J. Invest. Dermatol. 130(11):2611-2620(2010)Plantinga, T.S., et al. J. Acquir. Immune Defic. Syndr. 55(1):87-94(2010)Cunha, C., et al. Blood (2010) In press :van der Velden, W.J., et al. Clin. Immunol. 136(2):302-306(2010)Kankkunen, P., et al. J. Immunol. 184(11):6335-6342(2010)